Dr. Schiff joined Fund I in September of 1999 and currently serves as one of the Managing Partners. Prior to joining Fund I, Dr. Schiff practiced internal medicine at The New York Presbyterian Hospital where he maintains his position as a Clinical Assistant Professor of Medicine.

Dr. Schiff currently serves as a director of Agile Therapeutics (NASDAQ:AGRX), ARMGO Pharma, PowerVision,  and Zeltiq Aesthetics (NASDAQ:ZLTQ). Previously he served as a director of Adams Respiratory Therapeutics, ArgiNOx Pharmaceuticals, Barrier Therapeutics, Bioenvision, Cempra Pharmaceuticals, CardioKine, Dynova Laboratories, Miramar Labs, Myogen, Planet Technologies, Sirion Therapeutics, SkinMedica, and TransEnterix. In addition, Dr. Schiff was a board observer to Quintiles.

Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia University and his Sc.B. with honors in Neuroscience from Brown University.

Dennis Purcell
Steven A. Elms
Andrew Schiff
Aftab R. Kherani
Stacey D. Seltzer
Anthony Y. Sun
Brett I.W. Zbar
Josh Bilenker
Dov A. Goldstein
Lloyd E. Appel
Robert J. Wenzel
Jan Hoerrner
Cecilia Sun
Ayman Sabi
Robert Taber